Investors Buzz: Radian Group, Staples, US Airways Group, Arena Pharmaceuticals

Lakeway, NY -- (SBWIRE) -- 03/05/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Radian Group Inc. (NYSE:RDN) augmented 3.55% to $10.22 in the pre-market trading hours. The Company has completed its previously announced concurrent public offerings of 39.1 million shares of common stock and $400 million principal amount of convertible senior notes due 2019. The Company received aggregate net proceeds of approximately $299.5 million from the Common Stock Offering and $389.8 million from the Convertible Notes Offering.

Is RDN a Still a Buy after the Solid momentum? Let’s Find out Here

Staples, Inc. (NASDAQ:SPLS) closed at $13.05. Staples, Inc. will hold its quarterly conference call to discuss fourth quarter and fiscal 2012 results on March 6, 2013 at 8:00 a.m. Eastern Time. The Company is the world's largest office products company and second largest internet retailer.

Is SPLS a Strong Buying Opportunity After The Recent Slump? Find out Here

US Airways Group, Inc. (NYSE:LCC) moved up 0.79% to $14.01 in the pre-market trading hours. US Airways Group Inc. said the U.S. Justice Department extended an antitrust review of its proposed merger with American Airlines parent AMR Corp asking the companies for more information. The airlines said they will continue cooperating with the antitrust division as it conducts its review of the proposed merger. The deal is still expected to close in the third quarter of 2013.went up 0.41% to $51.51 in the pre-market trading hours.

Should LCC Buy LCC After The Recent Movement? Let’s Find out Here

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) decreased 0.73% to $8.13 pre-market trading hours. The Company is still waiting for federal regulators to make a decision about the status of its weight loss drug Belviq. The Food and Drug Administration approved Belviq on June 27, but the drug has not gone on sale yet. The Drug Enforcement Administration is proposing that Belviq be classified as a Schedule IV controlled substance, which means it has a relatively low potential for abuse.

Recently, the company released fourth quarter results. The revenues were $1.9 million in the fourth quarter of 2012 compared to $2.1 million in the fourth quarter of 2011. Research and development expenses were $13.9 million in the fourth quarter of 2012 from $13.1 million in the fourth quarter of 2011.

Is ARNA a Strong Buying Opportunity After The Recent Slump? Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.